Overview
This study aims to verify the efficacy / effectiveness of treatment with transcranial direct therapy (TDCS) in patients with Persistent Covid who present headaches, migraines and chronic pain, such as arthralgias and myalgias.
Transcranial Direct Therapy is used in the field of Physiotherapy and Rehabilitation, with results that prove to be effective for the treatment of patients suffering from symptoms such as migraines, headaches, chronic pain, fibromyalgia or chronic neuropathic pain.
As can be seen, in the case of patients with Persistent Covid we find several of these symptoms, so it is suggested that, if Transcranial Direct Current Therapy (TDCs) is giving such good results, relieving these symptoms, why can not give such good results and help so much in patients with Persistent Covid, If many of the symptoms are the same, even if the origin or cause is different.
Eligibility
Inclusion Criteria:
- Patients with Persistent Covid
- Men and women
- All ages from 16 years old
- Patients who passed the Covid in its acute phase in an asymptomatic, mild and severe way.
Exclusion Criteria:
- Patients without confirmation with positive PCR in the acute phase of Covid-19
- Patients with Persistent Covid who do not have at least one of these symptoms: migraines, headaches, chronic pain, neuropathic pain, arthralgia, myalgias
- Patients with pacemaker / defibrillator
- Patients with brain implants
- Patients with cranial fractures
- Pregnant
